CL2024002725A1 - Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo - Google Patents

Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo

Info

Publication number
CL2024002725A1
CL2024002725A1 CL2024002725A CL2024002725A CL2024002725A1 CL 2024002725 A1 CL2024002725 A1 CL 2024002725A1 CL 2024002725 A CL2024002725 A CL 2024002725A CL 2024002725 A CL2024002725 A CL 2024002725A CL 2024002725 A1 CL2024002725 A1 CL 2024002725A1
Authority
CL
Chile
Prior art keywords
nmo
aqp4
aquaporin
novel treatment
mhc
Prior art date
Application number
CL2024002725A
Other languages
English (en)
Spanish (es)
Inventor
Wischhusen Jörg
Bruttel Valentin
Mamatha Jayaram Shriya
Ahsan Fadhil
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of CL2024002725A1 publication Critical patent/CL2024002725A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2024002725A 2022-03-24 2024-09-11 Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo CL2024002725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22164161.6A EP4249062A1 (en) 2022-03-24 2022-03-24 Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Publications (1)

Publication Number Publication Date
CL2024002725A1 true CL2024002725A1 (es) 2025-02-14

Family

ID=81325683

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002725A CL2024002725A1 (es) 2022-03-24 2024-09-11 Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo

Country Status (12)

Country Link
US (1) US20250205322A1 (cg-RX-API-DMAC7.html)
EP (2) EP4249062A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510786A (cg-RX-API-DMAC7.html)
KR (1) KR20240164796A (cg-RX-API-DMAC7.html)
CN (1) CN119110810A (cg-RX-API-DMAC7.html)
AU (1) AU2023237632A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250911A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002725A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024012332A2 (cg-RX-API-DMAC7.html)
IL (1) IL314754A (cg-RX-API-DMAC7.html)
MX (1) MX2024011666A (cg-RX-API-DMAC7.html)
WO (1) WO2023180549A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061917A1 (en) * 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234017B2 (en) * 2012-12-11 2016-01-12 The Regents Of The University Of California Aquaporin-4 peptide compositions and methods of use thereof
SG11201909290TA (en) * 2017-04-07 2019-11-28 Uti Lp Assay to measure the potency of receptor-ligand interactions in nanomedicines
CA3063959A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
WO2021184017A1 (en) * 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders

Also Published As

Publication number Publication date
CO2024012332A2 (es) 2024-09-30
CA3250911A1 (en) 2023-09-28
US20250205322A1 (en) 2025-06-26
EP4249062A1 (en) 2023-09-27
KR20240164796A (ko) 2024-11-20
WO2023180549A1 (en) 2023-09-28
MX2024011666A (es) 2024-09-27
AU2023237632A1 (en) 2024-08-15
CN119110810A (zh) 2024-12-10
EP4499231A1 (en) 2025-02-05
IL314754A (en) 2024-10-01
JP2025510786A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
CL2021001278A1 (es) Vesículas extracelulares modificadas y sus usos
CY1123315T1 (el) Απο-ανοσοποιημενα, ικριωματα υπομοναλων α τοξινων shiga και μορια στοχευσης-κυτταρων περιλαμβανοντας τα ιδια
CR20180492A (es) Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer
MX2023002181A (es) Anticuerpos anti-ror1 y proteinas de union biespecificas relacionadas.
CO2025000513A2 (es) Anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1, composiciones que comprenden anticuerpos anti-ror1 o conjugados de anticuerpos anti-ror1 y métodos para hacer y usar anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1
PE20190436A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1
CO2024012332A2 (es) Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo
PE20121636A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
CL2024001738A1 (es) Vacunas peptídicas
CL2021002459A1 (es) Péptidos y combinaciones de péptidos para uso en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093)
BR112022017032A2 (pt) Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas.
UY38200A (es) Conjugados de tirosina-tirosina de péptido cíclico acoplado a péptido de fusión de glp-1 y sus usos
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
AR122659A1 (es) Anticuerpos biespecíficos para linfocitos t activados por proteasa
CL2022003205A1 (es) Cisteína proteasa
CO2025009946A2 (es) Proteínas de unión al antígeno anti-tnfr2 y sus usos
CL2023000326A1 (es) Péptidos y sus combinaciones para su uso en inmunoterapia contra una infección por sars-cov-2 (covid-19)
CL2024002724A1 (es) Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson
CO2024003578A2 (es) Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
CO2024013220A2 (es) Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog
CO2026004947A2 (es) Proteínas de unión al receptor de transferrina y usos de estas
CO2025011125A2 (es) Conjugados anticuerpo-fármaco anti-cd70
CO2024012945A2 (es) Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1
PE20250119A1 (es) Peptidos y metodos para el tratamiento de neuromielitis optica
CO2025008076A2 (es) Proteínas de fusión fc de il-12